Myocarditis and Pericarditis

Angita Jain; Katelyn A. Bruno; Akira Matsumori; Leslie T Jr. Cooper; Mohamad Yamani; De Lisa Fairweather

doi:10.1016/B978-0-12-820472-6.00091-8

Myocarditis and Pericarditis

Angita Jain, Katelyn A. Bruno, Akira Matsumori, Leslie T Jr. Cooper, Mohamad Yamani, De Lisa Fairweather

Cardiovascular Diseases

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Myocarditis and pericarditis are defined as inflammation of the myocardium and pericardium, respectively, according to the current WHO classification. These diseases are usually self-limiting but may present with impaired cardiac function, arrhythmias or cardiogenic shock. This review discusses the management of myocarditis and pericarditis based on the current guidelines of the American College of Cardiology and the European Society of Cardiology. Treatment consists of specific therapy aimed at the cause (i.e., viral, fulminant, autoimmune) and nonspecific therapy aimed at the clinical manifestations such as heart failure or arrhythmias.

Original language	English (US)
Title of host publication	Comprehensive Pharmacology
Publisher	Elsevier
Pages	413-431
Number of pages	19
Volume	4
ISBN (Electronic)	9780128204726
DOIs	https://doi.org/10.1016/B978-0-12-820472-6.00091-8
State	Published - Jan 1 2022

Keywords

Autoimmune
COVID-19
Management
Myocarditis
Pathogenesis
Pericarditis
Therapy
Treatment
Virus

ASJC Scopus subject areas

Medicine(all)
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1016/B978-0-12-820472-6.00091-8

Cite this

@inbook{1c19a69b0d8f42d797635a6687947bdc,

title = "Myocarditis and Pericarditis",

abstract = "Myocarditis and pericarditis are defined as inflammation of the myocardium and pericardium, respectively, according to the current WHO classification. These diseases are usually self-limiting but may present with impaired cardiac function, arrhythmias or cardiogenic shock. This review discusses the management of myocarditis and pericarditis based on the current guidelines of the American College of Cardiology and the European Society of Cardiology. Treatment consists of specific therapy aimed at the cause (i.e., viral, fulminant, autoimmune) and nonspecific therapy aimed at the clinical manifestations such as heart failure or arrhythmias.",

keywords = "Autoimmune, COVID-19, Management, Myocarditis, Pathogenesis, Pericarditis, Therapy, Treatment, Virus",

author = "Angita Jain and Bruno, {Katelyn A.} and Akira Matsumori and Cooper, {Leslie T Jr.} and Mohamad Yamani and Fairweather, {De Lisa}",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-820472-6.00091-8",

language = "English (US)",

volume = "4",

pages = "413--431",

booktitle = "Comprehensive Pharmacology",

publisher = "Elsevier",

}

TY - CHAP

T1 - Myocarditis and Pericarditis

AU - Jain, Angita

AU - Bruno, Katelyn A.

AU - Matsumori, Akira

AU - Cooper, Leslie T Jr.

AU - Yamani, Mohamad

AU - Fairweather, De Lisa

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Myocarditis and pericarditis are defined as inflammation of the myocardium and pericardium, respectively, according to the current WHO classification. These diseases are usually self-limiting but may present with impaired cardiac function, arrhythmias or cardiogenic shock. This review discusses the management of myocarditis and pericarditis based on the current guidelines of the American College of Cardiology and the European Society of Cardiology. Treatment consists of specific therapy aimed at the cause (i.e., viral, fulminant, autoimmune) and nonspecific therapy aimed at the clinical manifestations such as heart failure or arrhythmias.

AB - Myocarditis and pericarditis are defined as inflammation of the myocardium and pericardium, respectively, according to the current WHO classification. These diseases are usually self-limiting but may present with impaired cardiac function, arrhythmias or cardiogenic shock. This review discusses the management of myocarditis and pericarditis based on the current guidelines of the American College of Cardiology and the European Society of Cardiology. Treatment consists of specific therapy aimed at the cause (i.e., viral, fulminant, autoimmune) and nonspecific therapy aimed at the clinical manifestations such as heart failure or arrhythmias.

KW - Autoimmune

KW - COVID-19

KW - Management

KW - Myocarditis

KW - Pathogenesis

KW - Pericarditis

KW - Therapy

KW - Treatment

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=85151195478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151195478&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-820472-6.00091-8

DO - 10.1016/B978-0-12-820472-6.00091-8

M3 - Chapter

AN - SCOPUS:85151195478

VL - 4

SP - 413

EP - 431

BT - Comprehensive Pharmacology

PB - Elsevier

ER -

Myocarditis and Pericarditis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this